Pharmasum Therapeutics AS
Addressing Alzheimer’s via Down syndrome
This article was originally published in Start Up
Most individuals with Down syndrome who live long enough will develop Alzheimer’s disease, and Pharmasum Therapeutics AS hopes to develop an AD program by targeting a protein kinase that may underlie that association. The company intends to develop agents to treat AD in individuals with DS, a large and growing market, and potentially all other patients afflicted with Alzheimer’s.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.